The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo - PubMed (original) (raw)
. 2005 Jan-Dec;11(1-12):1-15.
doi: 10.2119/2006-00005.Dinarello.
Gianluca Fossati, Eli C Lewis, Jae-Kwon Lee, Giulia Porro, Paolo Pagani, Daniela Modena, Maria Lusia Moras, Pietro Pozzi, Leonid L Reznikov, Britta Siegmund, Giamila Fantuzzi, Charles A Dinarello, Paolo Mascagni
Affiliations
- PMID: 16557334
- PMCID: PMC1449516
- DOI: 10.2119/2006-00005.Dinarello
The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo
Flavio Leoni et al. Mol Med. 2005 Jan-Dec.
Abstract
We studied inhibition of histone deacetylases (HDACs), which results in the unraveling of chromatin, facilitating increased gene expression. ITF2357, an orally active, synthetic inhibitor of HDACs, was evaluated as an anti-inflammatory agent. In lipopolysaccharide (LPS)-stimulated cultured human peripheral blood mononuclear cells (PBMCs), ITF2357 reduced by 50% the release of tumor necrosis factor-alpha (TNFalpha) at 10 to 22 nM, the release of intracellular interleukin (IL)-1alpha at 12 nM, the secretion of IL-1beta at 12.5 to 25 nM, and the production of interferon-gamma (IFNgamma) at 25 nM. There was no reduction in IL-8 in these same cultures. Using the combination of IL-12 plus IL-18, IFNgamma and IL-6 production was reduced by 50% at 12.5 to 25 nM, independent of decreased IL-1 or TNFalpha. There was no evidence of cell death in LPS-stimulated PBMCs at 100 nM ITF2357, using assays for DNA degradation, annexin V, and caspase-3/7. By Northern blotting of PBMCs, there was a 50% to 90% reduction in LPS-induced steady-state levels of TNFalpha and IFNgamma mRNA but no effect on IL-1beta or IL-8 levels. Real-time PCR confirmed the reduction in TNFalpha RNA by ITF2357. Oral administration of 1.0 to 10 mg/kg ITF2357 to mice reduced LPS-induced serum TNFalpha and IFNgamma by more than 50%. Anti-CD3-induced cytokines were not suppressed by ITF2357 in PBMCs either in vitro or in the circulation in mice. In concanavalin-A-induced hepatitis, 1 or 5 mg/kg of oral ITF2357 significantly reduced liver damage. Thus, low, nonapoptotic concentrations of the HDAC inhibitor ITF2357 reduce pro-inflammatory cytokine production in primary cells in vitro and exhibit anti-inflammatory effects in vivo.
Figures
Figure 1
Time course of protein hyperacetylation in LPS-stimulated PBMCs. Resting human PBMCs from a healthy donor were incubated with LPS only (10 ng/mL) or LPS in the presence of ITF2357 (100 nM) or SAHA (100 nM). At the indicated times, the cells were lysed and total protein extracts analyzed by Western blotting using an antibody to acetylated lysines. The results are representative of 1 of 3 donors with similar observations.
Figure 2
Effect of ITF2357 on the secretion of TNFα in LPS-stimulated PBMCs. After an overnight rest, PBMCs were preincubated with increasing concentrations of ITF2357 for 1 h at 37°C, followed by LPS (10 ng/mL) for an additional 20 h. TNFα released into the supernatant was measured, and the percent reduction from LPS only (set at 100%) is indicated on the vertical axis. The data are presented as mean percent change (± SEM) of 6 donors. The dashed line indicates inhibition of 50% of TNFα induced by LPS only. *P < 0.05; **P < 0.01 from LPS only.
Figure 3
Effect of ITF2357 on intracellular IL-1α and secreted IL-1β from LPS-stimulated PBMCs. Freshly obtained PBMCs were preincubated for 1 h with increasing nanomolar concentrations of ITF2357 and then stimulated with LPS (10 ng/mL) for 24 hours. (A) Levels of intracellular IL-1α are shown as the percent change from LPS only (set at 100%) as indicated on the vertical axis. (B) Levels of secreted IL-1β are shown as the percent change from LPS only. The data are the mean percent change ± SEM of 6 donors. The dashed line indicates inhibition of 50%. (C) FACS analysis of percent of total cell PI staining expressed at sub-G1 cell cycle. Mean ± SEM of 4 donors are shown. Cells in sub-G1 cycle are from the same cultures shown in B. *P < 0.05; **P < 0.01 from LPS only.
Figure 4
Caspase 3/7 activation and nucleosome formation. Purified monocytes were incubated with and without ITF2357 (as shown under the horizontal axis). After 1 h, LPS (10 ng/mL) was added to some wells. After 24 h, caspase activation and nucleosome formation were assayed. The data are expressed as fold increase (mean ± SEM, n = 3 donors) over monocytes without ITF2357.
Figure 5
Effect ITF2357 on apoptosis and necrosis in PBMCs. (A) PBMCs in RPMI were incubated with increasing concentrations of ITF2357 for 1 h followed by the addition of LPS (10 ng/mL) to appropriate wells. After 24 h at 37° C, the percentage of annexin-V– and PI-positive PBMCs was determined. The data are the mean ± SEM of 5 separate experiments/donors. (B) FACS analysis of PI and annexin V staining in control PBMCs. (C) PI and annexin V staining in PBMCs incubated with 100 nM ITF2357. (D) PI and annexin V staining in PBMCs incubated with 1000 nM ITF2357. The data in B, C, and D are from 1 representative experiment.
Figure 6
Effect of ITF2357 on apoptosis and necrosis in monocytes. Purified monocytes in RPMI were incubated with increasing concentrations of ITF2357 for 1 h followed by the addition of LPS (10 ng/mL) to appropriate wells. After 24 h at 37° C, the percentage of annexin-V– and PI-positive cells was determined. (A) The data are the mean ± SEM of 3 separate experiments/donors. (B) FACS analysis of PI and annexin V staining in control monocytes. (C) PI and annexin V staining in monocytes incubated with 100 nM ITF2357. (D) PI and annexin V staining in monocytes incubated with 1000 nM ITF2357. The data in B, C, and D are from 1 representative experiment.
Figure 7
Effect of ITF2357 on LPS-induced IFNγ production. Freshly obtained PBMCs were preincubated for 1 h with increasing concentrations of ITF2357 (horizontal axis) and stimulated with LPS (10 ng/mL) for 24 h. Levels of secreted IFNγ are shown in ng/mL on the vertical axis. The data are presented as the mean percent change ± SEM of 4 donors and the dashed line indicates inhibition of 50%. *P < 0.05; **P < 0.01 from LPS only.
Figure 8
Suppression of IL-18/IL-12–induced IFNγ by ITF2357. Freshly cultured PBMCs were pretreated with increasing concentrations of ITF2357 (shown under horizontal axis) for 1 h as described in Figure 7. The cells were stimulated with the combination of IL-18 (10 ng/mL) plus IL-12 (1 ng/mL) (left panel). Matching cultures were similarly stimulated in the presence of IL-1Ra (10 μg/mL, middle panel) or TNF-bp (1 μg/mL, right panel). IFNγ was measured in the supernatants after 24 hours. Data are mean ± SEM of IFNγ in ng/mL of 4 donors. *P < 0.05; **P < 0.01 compared with no ITF2357.
Figure 9
Stimulus-dependent suppression of IFNγ by ITF2357. (A) LPS-induced IFNγ from resting PBMCs stimulated with LPS (10 ng/mL). Resting PBMCs were preincubated with ITF2357 as indicated for 1 h at 37° C before the addition of LPS. Mean ± SEM of IFNγ in pg/mL of 4 donors. (B) After preincubation with ITF2357, the cells from the same donors were stimulated with anti-CD3 (500 ng/mL). After 24 h, IFNγ was measured in the supernatants. Mean ± SEM of IFNγ in pg/mL of 3 donors are shown.
Figure 10
Effect of ITF2357 on IL-6 production. Freshly cultured PBMCs were preincubated with ITF2357 for 1 h and then stimulated with the combination of IL-18 (10 ng/mL) and IL-12 (1 ng/mL) as in Figure 8. Open bars indicate PBMCs at a concentration of 2.5 million cells/mL, and solid bars represent PBMCs at 5 million cells/mL. Mean ± SEM of IL-6 measured in the supernatant of triplicate wells after 24 h are shown for 2 donors. *P < 0.05; **P < 0.01 compared with no ITF2357.
Figure 11
Inhibition of IL-6 by ITF2357 is independent of IL-1β and TNFα. Left panel depicts the dose-response inhibition of IL-18/IL-12–induced IL-6 by increasing concentrations of ITF2357. Freshly isolated PBMCs were preincubated with ITF2357 for 1 h. The combination of IL-18/IL-12 was added for an additional 20 h, and IL-6 was measured in the supernatants. Matching cultures were similarly stimulated in the presence of IL-1Ra (10 μg/mL, middle panel) or TNF-bp (1 μg/mL, right panel). Data are mean ± SEM of IL-6 in ng/mL of 4 donors. *P < 0.05; *P < 0.01 compared with no ITF2357.
Figure 12
Steady-state mRNA levels in PBMCs. Northern blot analysis of specific cytokine mRNA extracted from resting PBMCs at times indicated. Lane 1, unstimulated PBMCs; lane 2, ITF2357 only (50 nM); lane 3, LPS (10 ng/mL); lane 4, LPS in the presence of ITF2357 (50 nM). In addition, LPS-induced TNFα, IL-1β, IFNγ, and IL-8 were measured in the supernatant by specific ELISA, and the percent inhibition of LPS-induced cytokines by ITF2357 is indicated under the respective bands and time points are indicated. ND = not determined. Shown are the results of a single donor. Similar results were obtained in a second donor.
Figure 13
Real-time PCR of steady-state TNFα mRNA. Real-time PCR was performed on RNA extracted from resting PBMCs 4 h after stimulation with LPS (10 ng/mL) in the presence of 50 nM ITF2357. The data were calculated as mRNA in picograms per nanogram of 18S RNA. A value of 1.0 was assigned for the unstimulated control of each donor (indicated as A, B, and C), and the fold change was calculated for each donor.
Figure 14
Effect of oral ITF2357 on LPS-induced circulating cytokines. (A) Mice received ITF2357 by gavage 1 h before intraperitoneal LPS (30 mg/kg). Dose-response of oral ITF2357 on serum TNFα (mean ± SEM) 90 min after LPS is shown. Control mice received an oral dose of water followed by LPS; 6 mice in each group. (B) Using another group of mice, an identical study was performed but blood was obtained 6 h after LPS. Mean ± SEM IFNγ is shown for 6 mice per group. (C) Similar to A and B, mice were pretreated with either dexamethasone (DEX at 10 mg/kg) or increasing doses of oral ITF2357 followed by an intravenous injection of anti-mouse CD3 (10 μg/kg). Serum was obtained 90 min after the anti-CD3 antibody and mean ± SEM TNFα is shown (5 mice per group). *P < 0.05; **P < 0.01 compared with water vehicle.
Figure 15
Effect of ITF2357 on ConA-induced hepatitis in BALB/C mice. BALB/C mice (10 per group) received either a single oral dose (100 μL) of 5 mg/kg of ITF2357 or an equivalent volume of water (Controls). After 30 min, both groups received an intravenous injection of ConA (200 μg per mouse). Mean ± SEM serum ALT are shown after 24 h. **P < 0.01 versus ConA with water vehicle.
Figure 16
Effect of ITF2357 on ConA-induced hepatitis in C57Bl/6 mice. C57BL/6 mice (10 per group) received either a single oral dose of 1 or 10 mg/kg ITF2357 (100 μL), whereas control mice received water (Controls). After 30 min, all mice received an intravenous injection of ConA (200 μg per mouse). Mean ± SEM serum ALT are shown after 24 hours. *P < 0.05 versus ConA with water vehicle.
Similar articles
- Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo.
Li S, Fossati G, Marchetti C, Modena D, Pozzi P, Reznikov LL, Moras ML, Azam T, Abbate A, Mascagni P, Dinarello CA. Li S, et al. J Biol Chem. 2015 Jan 23;290(4):2368-78. doi: 10.1074/jbc.M114.618454. Epub 2014 Dec 1. J Biol Chem. 2015. PMID: 25451941 Free PMC article. - The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Donà G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, Mascagni P. Leoni F, et al. Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2995-3000. doi: 10.1073/pnas.052702999. Epub 2002 Feb 26. Proc Natl Acad Sci U S A. 2002. PMID: 11867742 Free PMC article. - The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro.
Lewis EC, Blaabjerg L, Størling J, Ronn SG, Mascagni P, Dinarello CA, Mandrup-Poulsen T. Lewis EC, et al. Mol Med. 2011 May-Jun;17(5-6):369-77. doi: 10.2119/molmed.2010.00152. Epub 2010 Dec 22. Mol Med. 2011. PMID: 21193899 Free PMC article. - Inhibition of histone deacetylases in inflammatory bowel diseases.
Glauben R, Siegmund B. Glauben R, et al. Mol Med. 2011 May-Jun;17(5-6):426-33. doi: 10.2119/molmed.2011.00069. Epub 2011 Feb 22. Mol Med. 2011. PMID: 21365125 Free PMC article. Review. - Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.
Shein NA, Shohami E. Shein NA, et al. Mol Med. 2011 May-Jun;17(5-6):448-56. doi: 10.2119/molmed.2011.00038. Epub 2011 Jan 25. Mol Med. 2011. PMID: 21274503 Free PMC article. Review.
Cited by
- Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening.
Oikonomou A, Watrin T, Valsecchi L, Scharov K, Savino AM, Schliehe-Diecks J, Bardini M, Fazio G, Bresolin S, Biondi A, Borkhardt A, Bhatia S, Cazzaniga G, Palmi C. Oikonomou A, et al. Heliyon. 2024 Jul 3;10(13):e34033. doi: 10.1016/j.heliyon.2024.e34033. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39071567 Free PMC article. - HDAC inhibitors as a potential therapy for chemotherapy-induced neuropathic pain.
Manengu C, Zhu CH, Zhang GD, Tian MM, Lan XB, Tao LJ, Ma L, Liu Y, Yu JQ, Liu N. Manengu C, et al. Inflammopharmacology. 2024 Aug;32(4):2153-2175. doi: 10.1007/s10787-024-01488-x. Epub 2024 May 18. Inflammopharmacology. 2024. PMID: 38761314 Review. - ITF2357 regulates NF-κB signaling pathway to protect barrier integrity in retinal pigment epithelial cells.
Lim RR, Mahaling B, Tan A, Mehta M, Kaur C, Hunziker W, Kim JE, Barathi VA, Ghosh A, Chaurasia SS. Lim RR, et al. FASEB J. 2024 Mar 15;38(5):e23512. doi: 10.1096/fj.202301592R. FASEB J. 2024. PMID: 38430220 - Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy.
Holay N, Somma A, Duchow M, Soleimani M, Capasso A, Kottapalli S, Rios J, Giri U, Diamond J, Schreiber A, Piscopio AD, Van Den Berg C, Eckhardt SG, Triplett TA. Holay N, et al. Front Immunol. 2023 Sep 6;14:1260545. doi: 10.3389/fimmu.2023.1260545. eCollection 2023. Front Immunol. 2023. PMID: 37744352 Free PMC article. - The Importance of the "Time Factor" for the Evaluation of Inhibition Mechanisms: The Case of Selected HDAC6 Inhibitors.
Cellupica E, Caprini G, Fossati G, Mirdita D, Cordella P, Marchini M, Rocchio I, Sandrone G, Stevenazzi A, Vergani B, Steinkühler C, Vanoni MA. Cellupica E, et al. Biology (Basel). 2023 Jul 26;12(8):1049. doi: 10.3390/biology12081049. Biology (Basel). 2023. PMID: 37626935 Free PMC article.
References
- Yang X. Lysine acetylation and the bromodomain: a new partnership for signaling. Bioessays. 2004;26:1076–86. - PubMed
- Curtin ML. Current patent status of histone deacetylase inhibitors. Expert Opin Ther Patents. 2002;12:1375–84.
- Marks PA, et al. Histone deacetylases and cancer: causes and therapies. Nature Rev Cancer. 2001;1:194–202. - PubMed
- Richon VM, Zhou X, Rifkind RA, Marks PA. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis. 2001;27:260–4. - PubMed
- O’Connor OA, et al. Clinical development of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in aggressive non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease (HD) Blood. 2001;98:611a.
Publication types
MeSH terms
Substances
Grants and funding
- AI-15614/AI/NIAID NIH HHS/United States
- P01 HL068743/HL/NHLBI NIH HHS/United States
- CA-04 6934/CA/NCI NIH HHS/United States
- R01 AI015614/AI/NIAID NIH HHS/United States
- HL-68743/HL/NHLBI NIH HHS/United States
- R56 AI015614/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous